Jay A. Levy, MD

Wesleyan University, Middletown, CT, BA, 1960, Biology
Universite de Paris, France, 1961, Regeneration
Columbia University, New York, MD, 1965, Medicine and Virology

• 1965-1966
  Intern in Medicine, Hospital of the University of Pennsylvania
• 1966-1967
  First year resident in Medicine, Hospital of the University of Pennsylvania
• 1967-1970
  Staff Associate,National Cancer Institute, NIH, Bethesda, MD
• 1970-1971
  Second year resident, University of California, San Francisco (UCSF)
• 1971-1972
  Visiting Scientist, Hopital St. Louis (Prof. M. Boiron), Paris; Hopital Paul-Brousse (Dr. G. Mathe), ICIG, Paris
• 1972-1977
  Assistant Professor of Medicine, Research Associate, Cancer Research Institute, University of California San Francisco
• 1978-1979
  Visiting Scientist, Weizmann Institute, Rehovot, Israel (Prof. N. Haran-Ghera); Pasteur Institute, Paris (Prof. F. Jacob)
• 1978-1985
  Associate Professor of Medicine, and Microbiology and Immunology, University of California San Francisco
• 1985-present
  Professor, Dept of Med., Div of Hem/Onc and Research Assoc, Cancer Research Institute, UCSF

• (selected from over 400)
• Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, Oshiro LS. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225: 840-842, 1984.
• Levy JA, Mitra G, Mozen MM. Recovery and inactivation of infectious retroviruses added to factor VIII concentrates. Lancet ii: 722-723, 1984.
• Luciw PA, Potter SJ, Steimer K, Dina D, Levy JA. Molecular cloning of AIDS-associated retrovirus. Nature 312: 760-763, 1984.
• Levy JA, Shimabukuro J, McHugh T, Casavant C, Stites D, Oshiro L. AIDS-associated retroviruses (ARV) can productively infect other cells besides human T helper cells. Virology 147: 441-448, 1985.
• Sanchez-Pescador R, Power MD, Levy JA, et al. Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science 227: 484-492, 1985.
• Hoffman AD, Banapour B, Levy JA. Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology 147: 326-335, 1985.
• Levy JA, Cheng-Mayer C, Dina D, et. al. Replication of AIDS-associated retrovirus (ARV-2) in human and animal fibroblast cells transfected with a molecular clone of the virus. Science 232: 998-1001, 1986.
• *Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234: 1563-1566, 1986.
• *Cheng-Mayer C, Seto D, Tateno M, Levy JA: Biologic features of HIV that correlate with virulence in the host. Science 240: 80-82, 1988.
• Nelson JA, Wiley CA, Levy JA, et. al. Human immunodeficiency virus detected in bowel epithelium from patients with gastrointestinal symptoms. Lancet i: 259-262, 1988.
• Evans LA, Moreau J, Odehouri K, Legg H, Barboza A, Cheng-Mayer C, Levy JA. Characterization of a noncytopathic HIV-2 strain with unusual effects on CD4 expression. Science 240: 1522-1525, 1988.
• Homsy J, Meyer M, Tateno M, Clarkson S, Levy JA. The Fc and not the CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 244: 1357-1360, 1989.'
• Walker CM, Levy JA. A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology 66: 628-630, 1989.
• Walker CM, Erickson AL. Hsueh FC, Levy JA. Inhibition of HIV replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism. J Virol, 65:5921-5927, 1991.
• Mackewicz CE, Ortega HW, Levy JA. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 87: 1462-1466, 1991.
• Levy JA. Pathogenesis of HIV infection. Microbiol Rev, 57:183-289, 1993.
• Landay AL, Mackewicz C, Levy JA. An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol, 69:106-116, 1993.
• *Mackewicz CE, Lee F, Ortega H, Levy JA. The anti-HIV activity in CD8+ cell culture fluids is not associated with other known cytokines. Cell Immunol 153:329-343, 1994.
• Mackewicz CE, Yang LC, Lifson JD, Levy JA. Noncytolytic CD8+ cell anti-HIV responses and neutralizing antibody titers in primary HIV infection. Lancet 344:1671-1673, 1994.
• Mackewicz CE, DJ Blackbourn and JA Levy. CD8+ lymphocytes from HIV-1 seropositive individuals block HIV replication in CD4+ lymphocytes by inhibiting HIV RNA synthesis. PNAS. 92: 2308-2312, 1995.
• Barker E, Mackewicz CE, Levy JA. Effects of Th1 and Th2 cytokines on CD8+ cell anti-HIV response: implications for long-term survival. PNAS, 92:11135-11139, 1995.
• Blackbourn DJ, CE Mackewicz, JA Levy, et. al. Suppression of HIV replication by lymphoid tissue CD8+ cells correlates with the clinical state of HIV-infected individuals. PNAS, 93: 13125-13130, 1996.
• *Levy JA, Mackewicz C, Barker E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today, 17:217-224, 1996.
• Mackewicz CE, Barker E, Greco G, Reyes-Teran G, Levy JA. Do b-chemokines have clinical relevance in HIV infection? J Clin Invest 100:921-930, 1997.
• Barker E, Bossart KN, Levy JA. Primary CD8+ cells from HIV-infected individuals can suppress productive infection of macrophages independent of b-chemokines. PNAS, 95:1725-1729, 1998.
• Mackewicz CE, Garovoy MR, Levy JA. HLA compatibility requirements for CD8+ cell T-cell-mediated suppression of human immunodeficiency virus replication. J Virol 72: 10165-10170, 1998.
• Stranford SA, Skurnick J, Louria D, Osmond D, Chang S, Sninsky J, Ferrari G, Weinhold K, Lindquist, Levy JA. Lack of infection in HIV-exposed individuals is associated with a strong CD8+ cell noncytotoxic anti-HIV response. PNAS 96:1030-35, 1999.
• Mackewicz CE, Patterson, BK, Lee SA, Levy, JA. CD8+ cell non-cytotoxic anti-human immunodeficiency virus response inhibits expression of viral RNA but not reverse transcription or provirus integration. J. Gen Virol 81: 1261-64, 2000.
• Stranford SA, Levy JA et. al. Reduction in CD8+ cell noncytotoxic anti-HIV activity in subjects receiving HAART therapy during primary infection. PNAS. 98:597-602, 2001.
• Mackewicz CE, Wang B, Metkar S, Richey M, Froelich C, Levy JA. Lack of CD8+ cell anti-HIV factor in CD8+ cell granules. Blood, 102:180-183, 2003.
• Locher CP, Witt SA, Herdier BG, Abbey NW, Tenner-Racz K, Racz P, Kiviat NB, Murthy KK, Brasky K, Leland M, Levy JA. Increased viral replication and virulence after serial passage of human immunodeficiency virus type-2 in baboons. J Virol. 77: 77-88, 2003.
• Locher CP, Fujimura S, Murthy K, Brasky K, Leland M, Levy JA. Expression patterns of phenotypic markers on lymphocytes from human immunodeficiency virus type 2-infected baboons. AIDS Res Hum Retrovir. 19: 31-40, 2003
• *Mackewicz CE, Craik CS, Levy JA. The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors. Proc Natl Acad Sci (USA), 100, 3433-3438, 2003.
• Diaz L, Stone M, Mackewicz CE, Levy JA. Differential gene expression in CD8+ cells exhibiting non-cytotoxic anti-HIV activity. Virology. 311: 400-405, 2003.
• Mackewicz C, Yuan J, Tran P, Diaz L, Mack E, Selsted M, Levy JA. _-Defensins can have anti-HIV activity but are not CD8+ cell anti-HIV factors. AIDS, 17: F23-F32. 2003.